Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P3B3 | ISIN: US12591J2078 | Ticker-Symbol: CVGU
Siehe auch CSPC PHARMACEUTICAL GROUP LTD
Frankfurt
15.05.25 | 08:02
2,440 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
CSPC PHARMACEUTICAL GROUP LTD ADR Chart 1 Jahr
5-Tage-Chart
CSPC PHARMACEUTICAL GROUP LTD ADR 5-Tage-Chart

Aktuelle News zur CSPC PHARMACEUTICAL GROUP LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:58CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION4
DiCLSA Adds Basket Allocation on CSPC PHARMA/HANSOH PHARMA/Hengrui as CN Policy Environment Now More Supportive for Pharmas2
MoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - VONOPRAZAN FUMARATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL4
FrCSPC PHARMA (01093): PROXY FORM (REVISED) FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 30 MAY 2025 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)2
FrCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.3
FrCSPC PHARMA (01093): NEXT DAY DISCLOSURE RETURNS1
07.05.CLSA lifts CSPC Pharmaceutical stock target to HK$13.805
07.05.CLSA Adds CSPC PHARMA's TP to $13.8, Rating 'High-Conviction Outperform'3
CSPC PHARMACEUTICAL GROUP LTD ADR Aktie jetzt für 0€ handeln
02.05.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - JMT202 (RECOMBINANT FULLY HUMAN ANTI-BETA KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL ...2
30.04.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT ...1
28.04.CSPC PHARMA (01093): NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM2
28.04.CSPC PHARMA (01093): NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM3
28.04.CSPC PHARMA (01093): LETTER TO NEW REGISTERED SHAREHOLDERS AND REPLY FORM3
28.04.CSPC PHARMA (01093): PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 30 MAY 2025 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)1
28.04.CSPC PHARMA (01093): NOTICE OF ANNUAL GENERAL MEETING8
28.04.CSPC PHARMA (01093): PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, MANDATE TO GRANT OPTIONS AND RE-ELECTION OF RETIRING DIRECTORS ...4
28.04.CSPC PHARMA (01093): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT1
28.04.CSPC PHARMA (01093): 2024 ANNUAL REPORT4
28.04.BofAS Lifts CSPC PHARMA TP to HKD5.1, Maintains Underperform Rating5
25.04.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL3
Seite:  Weiter >>
97 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1